- Market Capitalization, $K 255,224
- Shares Outstanding, K 26,894
- Annual Sales, $ 48,870 K
- Annual Income, $ -3,360 K
- 60-Month Beta 0.93
- Price/Sales 5.42
- Price/Cash Flow 148.22
- Price/Book 12.12
|Period||Period Low||Period High||Performance|
| || |
-0.05 (-0.52%)since 08/24/21
| || |
-0.94 (-9.01%)since 06/24/21
| || |
+3.95 (+71.30%)since 09/24/20
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic'focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two...
Harrow (HROW) delivered earnings and revenue surprises of 15.38% and 16.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
--Highlights for Second Quarter 2021:
Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Harrow Health (HROW) closed at $8.97, marking a +0.56% move from the previous day.
Is (HROW) Outperforming Other Medical Stocks This Year?
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic'focused healthcare company, today announced that it has entered into an agreement with Sintetica, S.A., a growing pharmaceutical company focused on analgesics,...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday,...